Todos Medical Ltd (OTCQB:TOMDF) announced on Monday that it has signed an agreement with Aditx Therapeutics Inc (NASDAQ:ADTX), through which it has secured the rights to distribute Aditx’s immune-related AditxtScore COVID-19 scoring sytem, with planned availability in January 2021.
The company noted that blood samples will be collected by Todos and/or its network of partners and sent to Aditxt’s CLIA accredited AditxtScore Center for processing, with planned service availability expected early next year.
“After a thorough review of the immune-related COVID-19 testing market, we believe that Aditxt’s platform technology represents a unique multidimensional view of the immune system that will be critical to allow physicians and scientists to categorize immune responses to vaccines and therapeutic approaches for COVID-19 in order to determine which interventions to use for which patients in a personalized way,” said Todos Medical CEO Gerald Commissiong in a statement.
READ: Todos Medical has developed the technological tools for early disease detection
He added: “As vaccines for COVID-19 are rolled out, it is imperative that we evaluate patients’ immune status prior to and after vaccination, and track when immunity is gained and how long it might last with repeat immune testing. The AditxtScore for COVID-19 scoring system will initially include antibody and neutralizing antibodies, and will soon include T-cell and B-cell responses as well, which makes it the most comprehensive immune profiling tool for COVID-19 available in the market.”
Aditx Therapeutics CEO Amro Albanna also weighed in on the deal, stating: “This agreement marks a milestone for AditxtScoreand Aditxt as a whole. Todos Medical is Aditxt’s first commercial customer for our proprietary AditxtScore immune monitoring platform and its first application, AditxtScorefor COVID-19. As the availability of COVID-19 vaccines increases, the need to understand an individual’s immune profile to measure its effectiveness, increases as well. We look forward to working with the team at Todos and providing our innovative AditxtScore platform as a complement to the suite of testing solutions that they offer.”
Todos Medical, which provides the tools necessary for the early detection of life-threatening diseases such as cancer and COVID-19, recently reported $3.2 million in sales for November 2020, up 269% from October 2020 driven by increasing demand for the company’s PCR COVID-19 testing solutions.
Contact Sean at sean@proactiveinvestors.com
